Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
DOI:
https://doi.org/10.3889/oamjms.2019.342Keywords:
ERBB2, HER2/neu, Immunohistochemistry, Chromogenic in situ hybridisation, Breast carcinomaAbstract
BACKGROUND: The rapidly growing knowledge regarding factors controlling tumour growth, with the new modalities of therapy acting on the biological activity of the tumours draw the attention of most cancer researches nowadays and represent a major focus for clinical oncology practice. For the detection of HER2/neu protein overexpression and gene amplification, immunohistochemistry (IHC) and in-situ hybridisation (ISH) is the recommended techniques, respectively, with high concordance between the two techniques. The current United Kingdom recommendations for HER2/neu testing are either for a two-tier system using IHC with reflex ISH testing in equivocal positive cases, or a one-tier ISH strategy.
AIM: To compare the results of HER2/neu gene status in patients with breast carcinoma obtained by chromogenic in situ hybridisation with those obtained by immunohistochemistry, and to compare these results with hormonal receptors expression by immunohistochemistry and with age of patients.
METHODS: Immunohistochemistry technique was used for evaluation of status of estrogen receptors (ER) and progesterone receptors (PR) and HER2/neu protein expression in 448 Iraqi patients with invasive breast carcinoma with different grades and histological types and then chromogenic in situ hybridization (CISH) technique was applied for all scores of HER2/neu to detect the gene status and compare the results in all negative, equivocal and positive cases by immunohistochemistry (IHC). The cases were referred from different centres, and IHC and CISH techniques were done in central public health laboratory in Baghdad over 28 months, from July 2013 to November 2015. A comparison of the results was made to find the relationship between HER2/neu and hormone receptors status and other clinical parameters like patients age.
RESULTS: The mean age of the study cases was 49.08 years, ranging from 24 to 83 years. Of the 448 cases of breast carcinoma, 44 (9.8%) cases were of score 0 by IHC, none of them (0%) showed HER2/neu gene amplification by CISH. 71(15.8%) cases were of score 1 by IHC, 15 (21.12%) of them showed HER2/neu gene amplification by CISH, all were of low amplification. There were 306 (68.3%) cases of score 2 by IHC, of which 102 (33.33%) cases showed HER2/neu gene amplification by CISH, with 79 (25.81%) of them with low amplification and 23 (7.51%) cases with high amplification, while only one case (0.32%) remained in equivocal category. In score 3, all the 27 (6.0%) cases showed gene amplification with 12 (44.44%) cases with low amplification and 15 (55.55) cases with high amplification with overall percentage of gene amplification in score 3 of 100%. There was a significant inverse relationship between hormone receptors (ER and PR) status and HER2/neu gene amplification. No significant relationship was found between the patient’s age and HER2/neu gene amplification.
CONCLUSION: Although immunohistochemistry is a widely used, less expensive and reliable test, we strongly advice performance of chromogenic in situ hybridization in assessment of HER2/neu gene status in all cases diagnosed with breast carcinoma as significant number of cases that were reported as negative by immunohistochemistry showed positive amplification by chromogenic in situ hybridization and can get benefit from anti-HER2 targeted treatments.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology. 2011; 9: 16-32. https://doi.org/10.1038/nrclinonc.2011.177 PMid:22124364
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology. 2008; 19:1523-29. https://doi.org/10.1093/annonc/mdn169 PMid:18441328
Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO. Updated UK Recommendations for HER2 assessment in breast cancer. Journal of clinical pathology. 2015; 68(2):93-9. https://doi.org/10.1136/jclinpath-2014-202571 PMid:25488926 PMCid:PMC4316916
Pauletti G, Dandekar S, Rong H. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18:3651-64. https://doi.org/10.1200/JCO.2000.18.21.3651 PMid:11054438
Elledge RM, Green S, Ciocca D. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998; 4:7-12.
Wolff AC, Hammond ME, Hicks DG. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997-4013. https://doi.org/10.1200/JCO.2013.50.9984 PMid:24101045
Greer LT, Rosman M, Mylander WC. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg. 2013; 216:239-51. https://doi.org/10.1016/j.jamcollsurg.2012.09.007 PMid:23141136
Durgapal P, Mathur SR, Kalamuddin M. Assessment of her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: Experience from a tertiary care centre in india. Diagn Cytopathol. 2014; 42:726-31. https://doi.org/10.1002/dc.23088 PMid:24376261
Zustin J, Boddin K, Tsourlakis MC. HER-2/neu analysis in breast cancer bone metastases. J Clin Pathol. 2009; 62:542-6. https://doi.org/10.1136/jcp.2008.059717 PMid:19474354
Penault-Llorca F, Coudry RA, Hanna WM. Experts' opinion: recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. Breast. 2013; 22:200-2. https://doi.org/10.1016/j.breast.2012.12.004 PMid:23352656
Walker RA, Bartlett JM, Dowsett M. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008; 61:818-24. https://doi.org/10.1136/jcp.2007.054866 PMid:18381380
Press MF, Sauter G, Bernstein L. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005; 11:6598-607. https://doi.org/10.1158/1078-0432.CCR-05-0636 PMid:16166438
Sauter G, Lee J, Bartlett JM. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009; 27:1323-33. https://doi.org/10.1200/JCO.2007.14.8197 PMid:19204209
Arnould L, Roger P, Macgrogan Gl. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol. 2012; 25:675-82. https://doi.org/10.1038/modpathol.2011.201 PMid:22222637
Olsson H, Jansson A, Holmlund B, Gunnarsson C. Methods for evaluating HER2 status in breast cancer: comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue. Pathology and Laboratory Medicine International. 2013; 5:31-37. https://doi.org/10.2147/PLMI.S44976
Rosa FE, Santos RM, Rogatto SR, Domingues M. Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Brazilian Journal of Medical and Biological Research. 2013; 46:207-16. https://doi.org/10.1590/1414-431X20132483 PMid:23558859 PMCid:PMC3854374
Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014; 120:2657-64. https://doi.org/10.1002/cncr.28710 PMid:24930388 PMCid:PMC4232097
Allred DC. Issues and updates: evaluating oestrogen receptor, progesterone receptor, and HER2 in breast cancer. Modern Pathology. 2010; 23:S59. https://doi.org/10.1038/modpathol.2010.55 PMid:20436503
Reliable and simple detection of genomic alterations using light microscopy. ZytoDotR 2CTM - 2- Color CISH for the detection of genomic alterations. A user manual provided by ZytoVision GmbH - Fischkai 1, 27572 Bremerhaven- Germany. ZytoVision molecular diagnostics simplified, 2019:182-3. www. Zytovision.com
Lee AH, Key HP, Bell JA. The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation. J Clin Pathol. 2014; 67:573-5. https://doi.org/10.1136/jclinpath-2013-201978 PMid:24737400
Lundgaard Hansen B, Winther H, Moller K. Excessive section drying of breast cancer tissue prior to deparaffinisation and antigen retrieval causes a loss in HER2 immunoreactivity. Immunocytochemistry. 2008; 6:117-22.
Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB Jr. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg. 1990; 125:107-13. https://doi.org/10.1001/archsurg.1990.01410130113018 PMid:1688490
Iraqi cancer registry 2015 (page 29). Ministry of Health and Environment/Iraq- Iraqi Cancer Board, 2015. Accessed at: https://moh.gov.iq/upload/upfile/ar/833.pdf
Abd Ali Z, Hassan F, Yahya A. Immunohistochemical expression of HER2/neu receptors in Iraqi patients with endometrioid carcinoma. Journal of Clinical and Diagnostic Research. 2018, 12(11):5-8.
Schechter AL, Stern DF, Vaidyanathan L. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984; 312:513-516. https://doi.org/10.1038/312513a0 PMid:6095109
Albanell J, Bellmunt J, Molina R. Node-negative breast cancers with p53 (-)/HER2-neu (-) status may identify women with very good prognosis. Anticancer Res. 1996; 16:1027-32.
Ellis MJ, Coop A, Singh B. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19:3808-16. https://doi.org/10.1200/JCO.2001.19.18.3808 PMid:11559718
Berry DA, Muss HB, Thor AD. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000; 18:3471-79. https://doi.org/10.1200/JCO.2000.18.20.3471 PMid:11032587
Eswarachary V, Mohammed I, Jayanna P, PatilOkaly G, Nargund A, Dhondalay G. HER2/neu testing in 432 consecutive breast cancer cases using FISH and IHC - A comparative study. Journal of Clinical and Diagnostic Research. 2017, 11(4):1-5. https://doi.org/10.7860/JCDR/2017/25625.9521 PMid:28571140 PMCid:PMC5449786
Varga Z, Noske A, Ramach C, Padberg B and Moch H. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer. 2013; 13:615. https://doi.org/10.1186/1471-2407-13-615 PMid:24377754 PMCid:PMC3879657
Alwan N, Tawfeeq F, Muallah F. Breast cancer subtypes among Iraqi patients: identified by their Er, Pr and Her2 Status. J Fac Med Baghdad. 2017; 59(4):303-07. https://doi.org/10.32007/med.1936/jfacmedbagdad.v59i4.6
Barros FF. Biological characterisation of HER2 amplified breast cancer (Doctoral dissertation, University of Nottingham).
Jabbar N, Altaee M, Naji R. Correlation of Her-2/neu gene amplification by FISH and CISH with clinicopathological parameters of Iraqi breast carcinoma patients at central public health laboratories. Bio--Genetics Journal. 2016; 4(4):73-77.
Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, Cianciulli A, et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and thin prep®-processed breast cancer fine-needle aspirates: A sensitive and practical method in the trastuzumab era. The Oncologist. 2006; 11:878-86. https://doi.org/10.1634/theoncologist.11-8-878 PMid:16951391
Khashman B, Abdul-Sattar S. Determination of HER2 gene amplification using chromogenic in situ hybridization (CISH) in Iraqi patients with breast carcinoma. International Journal of Science and Research (IJSR). 2017; 6(8).
Manuelito A Madrid and Raymundo W Lo. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Research. 2004; 6( 5):1. https://doi.org/10.1186/bcr915 PMid:15318940 PMCid:PMC549176
Wolff AC, Hammond ME, Hicks DG. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014; 138:241-56. https://doi.org/10.5858/arpa.2013-0953-SA PMid:24099077 PMCid:PMC4086638
Goud KI, Dayakar S, Vijayalaxmi K, Babu SJ, Reddy PV. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res. 2012; 135(3):312-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Ali Hussein Mohammed Ali, Alaa Qasim Yahya, Haider Latteef Mohammed (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
